Bryan Garnier - CECONOMY (CEC) Starting to deliver... and soon beating expectations

Report

Bryan Garnier

Clement Genelot

Starting to deliver... and soon beating expectations

sWith a very resilient short-term performance opening the path to a potential FY guidance upgrade and self-help profitability levers out to 2025/26, we see Ceconomy as an attractive risk/reward stock within the brick & mortar specialized retail sector to play H2 2023 and H1 2024 while its Europ

13/07/2023 1 EN

Underlying

CECONOMY

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Clement Genelot

Other Reports on these Companies

Bryan Garnier

Ceconomy: still executing and delivering

Post another quarter of good execution and EBIT-FCF delivery, we now see Ceconomy meeting the top end of its FY EBIT guidance and have lifted our FY 2024-26 EPS by 4% and our PT to EUR3. Even after yesterday's share price drop, Ceconomy remains our top pick in the offline specialised retail segment

August 15, 2024 August 15, 2024 1 EN

Bryan Garnier

On the shelves now: Consumer weekly #34

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we take a look at underperformance by European, and especially French, equity indexe

June 24, 2024 June 24, 2024 1 EN

Bryan Garnier

On the shelves now: Consumer weekly #33

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we take a new look at the latest rumors around Shein London IPO. Happy reading!

June 17, 2024 June 17, 2024 1 EN

On the shelves now: Consumer weekly #42

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at the resolution of the ILA port strike which threatened the US holiday sho

41m 41m 1 EN

Bruno Bulic

Bruno Bulic

Abivax: Obefazimod in Crohn's disease clinical development

Abivax announced the start of clinical investigations in Crohn’s disease (CD) with obefazimod, disclosing the enrolment of the first patient. This phase IIb study (NCT06456593) named ENHANCE-CD is a multicentre, double-blind, randomized, placebo-controlled trial, with a design comparable to the com

October 4, 2024 October 4, 2024 1 EN

Bruno Bulic

Bruno Bulic

Abivax positive long-term Ph. II data

Abivax announced excellent interim data on the long-term open-label extension phase of it’s Ph. IIb at a reduced 25mg dose od (versus 50mg od in Ph. IIb). In this extension study, patients who completed the 4-year Ph. IIa or 2-year Ph. IIb with 50mg obefazimod with clinical response could enter thi

October 3, 2024 October 3, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Starting to deliver... and soon beating expectations

Ceconomy: still executing and delivering

On the shelves now: Consumer weekly #34

On the shelves now: Consumer weekly #33

On the shelves now: Consumer weekly #42

Abivax: Obefazimod in Crohn's disease clinical development

Abivax positive long-term Ph. II data

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe